The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: A review of the literature

Archives of Gynecology and Obstetrics

Volumn 288, Issue 3, 2013, Pages 581-585

  Tsikouras, Panagiotis ^a   Tsagias, Nikolaos ^a   Pinidis, Petros ^a   Csorba, Roland ^b   Vrachnis, Nikolaos ^c   Dafopoulos, Alexandros ^a   Bouchlariotou, Sophia ^a   Liberis, Anastasios ^a   Teichmann, Alexander Tobias ^b   Von Tempelhoff, Georg Friedrich ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Department of Obstetrics and Gynecology   (Germany)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Catumaxomab; Malignant ascites; Ovarian cancer

Indexed keywords

CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; MALIGNANT ASCITES; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT PLANNING; VOMITING;

ANTIBODIES, BISPECIFIC; ASCITES; CARCINOMA; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS;

EID: 84882676328     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2868-y     Document Type: Article

References (39)

1. Bookman MA (2009) Trials with impact on clinical management: first line. Int J Gynecol Cancer 19(Suppl 2):S55-S62 (review)
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200
3. Monk BJ, Choi DC, Pugmire G, Burger RA (2005) Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96(3):902-905
4. Cannistra SA (2010) Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 28(19):3101-3103
5. Cannistra SA (2002) Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20(5):1158-1160
6. Malayev Y, Levene R, Gonzalez F (2012) Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care 29(7):515-521
7. Barni S, Cabiddu M, Ghilardi M, Petrelli F (2011) A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol 79(2):144-153. doi: 10.1016/j.critrevonc.2010. 07.016
8. Shen-Gunther J, Mannel RS (2002) Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87(1):77-83
9. Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18(5):945-949
10. Woopen H, Sehouli J (2009) Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 29(8):3353-3359
11. Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15(2):59-72 (review)
12. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16(3):445-454
13. Beattie GJ, Smyth JF (1998) Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4(8):1899-1902
14. Kaufmann M, Schmid H, Raeth U, Grischke EM, Kempeni J, Schlick E, Bastert G (1990) Therapy of ascites with tumor necrosis factor in ovarian cancer. Geburtshilfe Frauenheilkd 50(9):678-682
15. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Meelichar B, Patenia R, Templin S, Scott W, Platsoucas CD (2000) Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-specific infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6(6):2268-2278
16. Walker J, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke Pearson D (2006) Intraperitoneal catheter outcomes in a phase 3 trial of intravenous versus intraperitoneal chemotherapy in an optimal stage 3 ovarian and primary peritoneal cancer: a Gynaecologic Oncology group study. Gynecol Oncol 100:27-32
17. Friedman RS, Deavers M, Liu J et al (2004) Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2:23
18. Revill Mely N, Bozzo J (2008) Catumaxomab anti-Ep-CAM monoclonal antibody. Drugs Future 33(5):385-391
19. Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2(2):129-136
20. Zeidler R, Mysliwietz J, Csanady M et al (2000) The Fc-region of a new class of intact biospecific antibody mediates activation of accessory cells and NK Cells and induces phagocytosis tumor cells. Br J Cancer 83:261-266
21. Riesenberg R, Buchner A, Pohla H et al (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (AEp-CAM X aCD3). J Histochem Cytochem 49:911-917
22. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfra B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S (2004) Opsonisation with a trifunctional bispecific (aCD3 × aEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM-positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25(4):841-848
23. Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 77(10):699-712 (review)
24. Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6(5):349-356 (review)
25. Heiss MM, Stroehlein MA, Jager M et al (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117(3):435-443
26. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13):3899-3905
27. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2-2209
28. Wimberger P, Gilet H, Gonschior A-K, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran S-E, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 23(8):1979-1985
29. Removab® Summary of product characteristics, Sept. 2011. http://www.ema.europa.eu/
30. Pietzner K, Chekerov R, Reinthaller A, Reimer D, Reimer T, Angleitner-Boubenizek L, Tschirschmann M, Lindhofer H, Braicu EI, Fotopoulou C, Sehouli J (2012) Matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy. J Clin Oncol 30(Suppl; abstr 5080)
31. Papanikolaou G, Fotopoulou C, Braicu I, Chekerov R, Schmidt SC, Pietzner K, Sehouli J (2011) First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam × anti-CD3) for epithelial ovarian cancer. Anticancer Res 31(8):2603-2608
32. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J (2012) Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 29(5):3416-3420
33. Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S (2012) Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Targt Oncol [Epub ahead of print]
34. Pietzner K, Jäger M, Schoberth A, Oskay-Özcelik G, Kuhberg M, Lindhofer H, Sehouli J (2012) First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol 29(2):1391-1396
35. Chekerov R, Reinthaller A, Reimer D, Reimer T, Angleitner-Boubenizek L, Halfen M, Lindhofer H, Braicu I, Oskay-özcelik G,Sehouli J (2010) Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: results from a phase II study. American Society of Clinical Oncology, vol 28, no 15-suppl (May 20 Supplement), p 5039
36. Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 69(6):617-625
37. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 14(28):18
38. Belau A, Pfisterer J, Wimpberger P, Kurzeder C, Du Bois A, Schouli J, Loibl S, Burchardi N (2007) Randomized, multicenter, two dose level open label phase II a study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 25(185) (June 20 Supplement 5556) (Part 1)
39. Stroehlein MA, Lordick F, Ruettinger D, Gruetzner U, Menzel H, Bartelheim K, Jaeger M, Lindhofer H (2005) Treatment of peritoneal carcinomatosis due to GI tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab: results of a phase I/II trial. J Clin Oncol 2005 ASCP Annual Meeting Proceedings, 23(165) (June 1 Supplement 2529) (Part I of II)